



## BRISIO INNOVATIONS INC.

FOR IMMEDIATE RELEASE

CSE: BZI / OTC: NTCEF

### Brisio Innovations Invests in ImmunoPrecise Antibodies Ltd.

**VANCOUVER, BRITISH COLUMBIA – (September 12, 2016)** -- Brisio Innovations Inc. (CSE: BZI) (PINKSHEETS: NTCEF) (the “**Company**”) is pleased to announce that it has completed an investment in ImmunoPrecise Antibodies Ltd. (“**IPA**”).

The Company has subscribed for a convertible note in the principal amount of \$97,500 (the “**Convertible Note**”). In the event that IPA completes a reverse takeover to list on stock exchange (“**Pubco**”), the principal amount of the Convertible Note will be convertible into 650,000 units of Pubco issued at a price of \$0.15 per unit.

Each Unit will consist of one common share of Pubco (a “**Pubco Share**”) and one share purchase warrant (“**Pubco Warrant**”). Each Pubco Warrant will entitle the Company to acquire one additional Pubco Share at a price of \$0.30 per share for a period of twelve (12) months from the date of issue of the Pubco Warrants.

IPA is a privately owned Canadian company located in Victoria, British Columbia, Canada. Their dedication to advancing antibody development has resulted in cutting-edge immunological innovations. IPA is comprised of experienced research and development scientists and encompasses a wide range of distinctive competencies, including innovative technologies required in the production of monoclonal and polyclonal antibodies. Their clients include leading companies in the biotech and pharmaceutical sector, as well as government and academic researchers.

Paul Andreola, President of Brisio Innovations states, “We are quite excited with the opportunity to invest in a rapidly growing organization at this early stage. Management have proven themselves to be very skillful in their execution of their business strategy as evidenced by their high profile clients and high rate of growth. We look forward to their continued performance and further success.”

Brisio Innovations Inc.  
Paul Andreola

---

President, CEO and Director  
(604) 644-0072  
[www.brisio.com](http://www.brisio.com),

### **About ImmunoPrecise Antibodies Ltd.**

ImmunoPrecise Antibodies Ltd. (IPA) is a privately owned Canadian company located in Victoria, British Columbia, Canada. IPA's dedication to advancing antibody development has resulted in cutting-edge immunological innovations. With over 25 years of experience in the custom antibody business, IPA provides high customer satisfaction through a customized professional approach.

IPA is comprised of experienced research and development scientists and encompasses a wide range of distinctive competencies, including innovative technologies required in the production of monoclonal and polyclonal antibodies. IPA prides itself on its high customer satisfaction and its clients have grown accustomed to receiving very thorough and professional service. IPA customizes its client's projects to generate antibodies that meets their specific needs. IPA's clients include: companies and scientists in the biotech and pharmaceutical sector, academic researchers and those employed by government. For more information visit: <http://www.immunoprecise.com/>

### **About Brisio Innovations**

Brisio Innovations Inc. invests its capital in companies and opportunities which management believes are undervalued and have potential for significant appreciation. The company makes investments in both public and private markets and focuses on opportunities in a wide variety of industries excluding the resource and resource service sectors. Brisio does not invest on behalf of any third party and it does not offer investment advice.

Disclaimer for Forward-Looking Information Certain statements in this news release are forward-looking statements, which reflect the expectations of management regarding potential future investments by the Company. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause the Company's actual results to differ materially from those expressed or implied by the forward looking statements.